Skip to the page

Data / Drug companies / Journey Medical Corporation

Journey Medical Corporation: 8 products in the FDA NDC directory, labeler code 69489

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Journey Medical Corporation (labeler code 69489) lists 8 products in the FDA National Drug Code Directory, covering 6 finished drugs by generic name. By type: 8 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on March 16, 2026.

The request: Watch Journey Medical Corporation (FDA labeler code 69489): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
69489
Products in commercial distribution
8
Packages
13
Finished drugs by generic name
6
Prescription products
8
Over the counter products
0
Flagged as original packager
8 of 8 products that carry the flag
Started marketing in the last 12 months
1
Products with a marketing end date set
1
Earliest marketing start
August 29, 2016
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
New drug applications (NDA)787.5%
Generic drugs (ANDA)112.5%

Products by type

TypeProductsShare
Prescription drugs8100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Sulconazole nitrate22
Minocycline21
Crotamiton13
Doxycycline hyclate161
Glycopyrronium11
Minocycline hydrochloride extended-release11

Dosage forms

Dosage formProductsShare
Cream225%
Aerosol, foam225%
Tablet112.5%
Cloth112.5%
Solution112.5%
Capsule112.5%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Eurax69489-311CreamNew drug applications (NDA)March 16, 2026
Emrosi69489-131CapsuleNew drug applications (NDA)March 1, 2025
Zilxi69489-212Aerosol, foamNew drug applications (NDA)October 1, 2022
Amzeeq69489-201Aerosol, foamNew drug applications (NDA)March 25, 2022
Exelderm69489-721SolutionNew drug applications (NDA)June 7, 2019
Exelderm69489-711CreamNew drug applications (NDA)June 7, 2019
Qbrexza69489-411ClothNew drug applications (NDA)June 28, 2018
Targadox69489-111TabletGeneric drugs (ANDA)August 29, 2016

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.